WYNNEFIELD CAPITAL INC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001251567

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth Tilt how tags are computed

Q2 2024 · 17 positions · Total reported value $222.49M · Top-10 concentration 97.4% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 12.5% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -18.6% · vs SPY -20.7% · Prev Value $145.38M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.0% · vs SPY -0.1% · Latest Value $121.78M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2024 13F filing, WYNNEFIELD CAPITAL INC disclosed 17 equity positions with a combined reported value of $222.49M. The filing implies a focused portfolio: its ten largest positions account for 97.4% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt.

The largest disclosed positions as of Q2 2024 were CDRE ($43.47M), DLHC ($38.88M), NATR ($37.28M). By sector, the heaviest allocations are Health Care 47.6%, Consumer Discretionary 18.0%. Versus the prior quarter, allocation shifted toward Materials (+3.1pp), Utilities (+1.5pp) and away from Other (-0.9pp), Health Care (-1.8pp).

Versus the prior quarter, WYNNEFIELD CAPITAL INC opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 12.5% of positions. The portfolio's overlap with the prior quarter was 74% of names.

Of the 6 positions fully exited versus the prior quarter, the largest were NOTVQ ($877.99K), APLS ($587.80K), LEAT ($92.75K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • NOTVQ INOTIV INC · prev qtr: $877.99K
  • APLS APELLIS PHARMACEUTICALS INC · prev qtr: $587.80K
  • LEAT LEATT CORP · prev qtr: $92.75K
  • GVP GSE SYS INC · prev qtr: $70.20K
  • RGS REGIS CORPORATION · prev qtr: $37.49K
  • SCTL SOCIETAL CDMO INC · prev qtr: $14.04K

Insider Transactions (Form 4)

Latest WYNNEFIELD CAPITAL INC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Wynnefield Capital, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 8 positions worth $121.78M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-73498 (status: Approved), registered 2012-03-30
  • Regulatory AUM (Form ADV): $184.52M as of 2026-06-15
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: wynnefieldcapital.com

Portfolio Structure

  • 8 positions · $121.78M reported value (Q3 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: LFCR (LIFECORE BIOMEDICAL INC) at 26.3%
  • Average position size: $15.22M

Sector Tilt

  • Health Care 76.9%
  • Consumer Discretionary 11.2%
  • Materials 5.3%
  • (classified holdings cover 98% of value)

Quarterly Activity

  • Q3 2026: 1 added, 1 reduced
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 47.6%
Materials 15.3%
Utilities 10.8%
Technology 0.8%
Other 6.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.30M $43.47M 19.54%
19.54%
Hold
2 3.68M $38.88M 17.47%
17.47%
Hold
3 2.47M $37.28M 16.75%
16.75%
Hold
4 490.00K $32.05M 14.40%
14.40%
Hold
5 4.92M $25.23M 11.34%
11.34%
Hold
6 2.73M $24.06M 10.81%
10.81%
Hold
7 1.98M $10.67M 4.79%
4.79%
Add
8 100.00K $1.99M 0.89%
0.89%
Hold
9 400.00K $1.61M 0.72%
0.72%
Hold
10 50.00K $1.56M 0.70%
0.70%
Hold
11 4.25M $1.53M 0.69%
0.69%
Hold
12 433.61K $1.49M 0.67%
0.67%
Hold
13 446.03K $1.10M 0.49%
0.49%
Hold
14 100.00K $878.00K 0.40%
0.40%
Reduce
15 50.00K $430.00K 0.19%
0.19%
Hold
16 50.95K $197.18K 0.09%
0.09%
Hold
17 28.13K $84.38K 0.04%
0.04%
Hold

FAQ

What did WYNNEFIELD CAPITAL INC buy in 2024-Q2?

In its 2024-Q2 13F filing, WYNNEFIELD CAPITAL INC reported 17 equity positions worth $222.49M in aggregate; its largest disclosed positions were CDRE ($43.47M), DLHC ($38.88M), NATR ($37.28M).

How large is WYNNEFIELD CAPITAL INC's portfolio?

WYNNEFIELD CAPITAL INC reported $222.49M of long equity holdings across 17 positions as of 2024-Q2. Top-10 holdings account for 97.4% of reported value.

What is WYNNEFIELD CAPITAL INC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/wynnefield-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →